RECURSION PHARMACEUTICALS, INC. Intangible Assets, Net (Excluding Goodwill)
RECURSION PHARMACEUTICALS, INC. (RXRX) had Intangible Assets, Net (Excluding Goodwill) of $282.89 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-05
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $282.89M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $294.07M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $309.90M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $322.34M.
| Period end | Intangible Assets, Net (Excluding Goodwill) | Intangible Assets, Net (Excluding Goodwill) as first filed |
|---|---|---|
| 2026-06-30 | $282.89M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $294.07M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $309.90M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $322.34M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $341.32M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $335.79M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $335.86M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $34.09M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $38.21M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $33.08M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $36.44M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $39.46M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $42.76M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $1.32M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $1.31M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $1.46M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $1.23M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $1.31M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $1.39M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $1.46M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $1.54M 10-Q · filed 2021-08-13 | |
| 2020-12-31 | $1.69M 10-K · filed 2022-03-23 | $1.69M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |